L19IL2/L19TNF in Skin Cancer Patients
Conditions:   BCC - Basal Cell Carcinoma;   SCC - Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Keratoacanthoma of Skin;   Malignant Adnexal Tumors of the Skin (MATS);   Tumors From Cutaneous T-cell Lymphoma (CTCL);   Kaposi Sarcoma Intervention:   Drug: L19IL2/L19TNF Sponsor:   Philogen S.p.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2022 Category: Research Source Type: clinical trials